SIC
BIO icon

Salem Investment Counselors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Salem Investment Counselors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6
Closed -$1.46K – 1186
2025
Q1 		$1.46K Buy
+6
New +$1.8K ﹤0.01% 1078
2021
Q2 		– Sell
-87
Closed -$50K – 905
2021
Q1 		$50K Hold
87
– – ﹤0.01% 457
2020
Q4 		$51K Hold
87
– – ﹤0.01% 430
2020
Q3 		$45K Buy
+87
New +$44.1K ﹤0.01% 383

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FPA
First Pacific Advisors El Segundo, California $7.14B AUM 21.51% 1-Year Est. Return

Salem Investment Counselors's BIO Position: Q2 2025 in Review

Salem Investment Counselors sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2025, closing a stake of 6 shares — an estimated $1.46K sold.

Salem Investment Counselors first reported a position in BIO in Q3 2020 and held it in 4 quarters. The position peaked at $51K in Q4 2020. 384 funds tracked by Wall St. Rank hold BIO as of Q2 2025.

  • Salem Investment Counselors reported no remaining Bio-Rad Laboratories Class A position as of Q2 2025 after selling out during the quarter.
  • Salem Investment Counselors sold 6 Bio-Rad Laboratories Class A shares in Q2 2025, an estimated $1.46K.
  • Salem Investment Counselors first reported a position in Bio-Rad Laboratories Class A in Q3 2020 and held it in 4 quarters.
  • Salem Investment Counselors's Bio-Rad Laboratories Class A position peaked at $51K in Q4 2020.
  • 384 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2025.

Based on Salem Investment Counselors's 13F filing for Q2 2025, filed 7 Jul 2025.